Add-on to Cognitive, Event-Related Potentials (ERP) and Electroencephalogram (EEG) Asymmetry in Affective Disorders

Depressive Illness Clinical Trial

Official title:

Add-on to Cognitive, ERP and EEG Asymmetry in Affective Disorders (#6559R) [Formerly #5723]

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03278938
• Other study ID #: #5723
• Status: Withdrawn
• Phase: Phase 4
• Start date: June 29, 2012
• Est. completion date: January 2016

Study information

• Verified date: March 2019
• Source: New York State Psychiatric Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Depressed patients unremitted after monotherapy with citalopram or bupropion will remit following six weeks treatment with the combination of citalopram and bupropion.

Description:

Participants in another study who did not remit during 12 weeks treatment with citalopram (to 40 mg/d) or bupropion (to 450 mg/d) will have citalopram (to 40 mg/d) or bupropion (to 450 mg/d) added for six weeks.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 2016
• Est. primary completion date: January 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 66 Years

Eligibility

Inclusion Criteria:

• non-remission in Protocol #6559R

• age 18-66

• signs informed consent

• physically healthy

Exclusion Criteria:

• bipolar disorder

• history of psychosis

• history of anorexia nervosa or bulimia

• history of seizure disorder, significant brain trauma or other medical reason to suspect increased seizure risk

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Illness
• Mood Disorders

Intervention

Drug:
• bupropion
FDA approved drug for treating depression
• citalopram
FDA approved treatment for depression

Locations

Country	Name	City	State
United States	New York State Psychiatric Institute	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
New York State Psychiatric Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hamilton Rating Scale	Decrease in score for Hamilton Rating Scale for Depression, 17-item version	weeks 6

External Links

•   web site for the Depression Evaluation Service, New York State Psychiatric Institute